TY - JOUR
T1 - UPPER GASTROINTESTINAL LESIONS AFTER POTASSIUM CHLORIDE SUPPLEMENTS
T2 - A CONTROLLED CLINICAL TRIAL
AU - Mcmahon, F. Gilbert
AU - Akdamar, Kemal
AU - Ryan, Jerome R.
AU - Ertan, Atilla
PY - 1982/11/13
Y1 - 1982/11/13
N2 - Liquid and solid formulations of potassium chloride (KCl) are widely used clinically. Enteric coated KCl preparations have occasionally produced intestinal ulceration, haemorrhage, obstruction, or even death. They were withdrawn from the market in 1965. Subsequently, wax-matrix slow-release KCl tablets were developed. Although these products were considered safe, gastrointestinal complications such as ulceration, haemorrhage, obstruction, and perforation have been reported. The effects of a new microencapsulated potassium chloride formulation on upper gastrointestinal tract mucosa was compared with that of a popular wax-matrix formulation in 48 healthy volunteers. After a week of KCl, subjects were gastroscoped, the endoscopist being blind to the type of preparation taken. Wax-matrix formulations were associated with a higher incidence of upper gastrointestinal lesions. The lesions were not accompanied by epigastric symptoms. Glycopyrrolate, given to some volunteers to decrease gastric emptying, aggravated the effects of potassium chloride.
AB - Liquid and solid formulations of potassium chloride (KCl) are widely used clinically. Enteric coated KCl preparations have occasionally produced intestinal ulceration, haemorrhage, obstruction, or even death. They were withdrawn from the market in 1965. Subsequently, wax-matrix slow-release KCl tablets were developed. Although these products were considered safe, gastrointestinal complications such as ulceration, haemorrhage, obstruction, and perforation have been reported. The effects of a new microencapsulated potassium chloride formulation on upper gastrointestinal tract mucosa was compared with that of a popular wax-matrix formulation in 48 healthy volunteers. After a week of KCl, subjects were gastroscoped, the endoscopist being blind to the type of preparation taken. Wax-matrix formulations were associated with a higher incidence of upper gastrointestinal lesions. The lesions were not accompanied by epigastric symptoms. Glycopyrrolate, given to some volunteers to decrease gastric emptying, aggravated the effects of potassium chloride.
UR - http://www.scopus.com/inward/record.url?scp=0019938421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019938421&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(82)90002-2
DO - 10.1016/S0140-6736(82)90002-2
M3 - Article
C2 - 6127542
AN - SCOPUS:0019938421
VL - 320
SP - 1059
EP - 1061
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 8307
ER -